Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines’ newly approved drug in pancreatic cancer. The post Tango Therapeutics Just Improved On This ‘Unprecedented’ Cancer Drug appeared first on Investor’s Business Daily.
Moderna stock crashed Thursday after a third-party leaked the purported cancer vaccine data ahead of a hotly anticipated presentation. The post Moderna Crashes 20% On Reportedly Leaked Cancer Vaccine Data appeared first on Investor’s Business Daily.
For income‑focused investors, covered calls can offer an additional way to improve the dividend yield on a stock like Pfizer. The post How To Boost The Dividend Yield On This Drugmaking Behemoth appeared first on Investor’s Business Daily.
Oncology-focused biotech firm BeOne Medicines pops into buy range, boosted by strong demand and stellar earnings growth. The post BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well. appeared first on Investor’s Business Daily.
Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company’s embattled drug, troriluzole. The post Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting appeared first on Investor’s Business…
Roche stock was unmoved early Thursday after the drugmaker matched sales expectations despite light pharma sales. The post Roche, In A Buy Zone, Matches Revenue Forecasts Despite Light Pharma Sales appeared first on Investor’s Business Daily.
Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart. The post Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans appeared first on Investor’s Business Daily.
Abbott stock took a hit Wednesday after the healthcare company said it plans to spin off its nutrition business. The post Abbott Topples After Announcing Plans To Spin Off Its Nutrition Business appeared first on Investor’s Business Daily.
Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday, but shares took a swim. The post Arcus Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer Data appeared first on Investor’s Business Daily.
Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment. The post Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher appeared first on Investor’s Business Daily.
